1
|
Aravindhan V, Yuvaraj S. Immune-endocrine network in diabetes-tuberculosis nexus: does latent tuberculosis infection confer protection against meta-inflammation and insulin resistance? Front Endocrinol (Lausanne) 2024; 15:1303338. [PMID: 38327565 PMCID: PMC10848915 DOI: 10.3389/fendo.2024.1303338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 01/02/2024] [Indexed: 02/09/2024] Open
Abstract
Tuberculosis patients with diabetes, have higher sputum bacillary load, delayed sputum conversion, higher rates of drug resistance, higher lung cavitary involvement and extra-pulmonary TB infection, which is called as "Diabetes-Tuberculosis Nexus". However, recently we have shown a reciprocal relationship between latent tuberculosis infection and insulin resistance, which has not been reported before. In this review, we would first discuss about the immune-endocrine network, which operates during pre-diabetes and incipient diabetes and how it confers protection against LTBI. The ability of IR to augment anti-TB immunity and the immunomodulatory effect of LTBI to quench IR were discussed, under IR-LTB antagonism. The ability of diabetes to impair anti-TB immunity and ability of active TB to worsen glycemic control, were discussed under "Diabetes-Tuberculosis Synergy". The concept of "Fighter Genes" and how they confer protection against TB but susceptibility to IR was elaborated. Finally, we conclude with an evolutionary perspective about how IR and LTBI co-evolved in endemic zones, and have explained the molecular basis of "IR-LTB" Antagonism" and "DM-TB Synergy", from an evolutionary perspective.
Collapse
Affiliation(s)
- Vivekanandhan Aravindhan
- Department of Genetics, Dr Arcot Lakshmanasamy Mudaliyar Post Graduate Institute of Basic Medical Sciences (Dr ALM PG IBMS), University of Madras, Chennai, India
| | | |
Collapse
|
2
|
Hoda Q, Ahmad S, Akhtar M, Abul Kalam Najmi, Pillai KK, Shibli Jameel Ahmad. Antihyperglycaemic and antihyperlipidaemic effect of poly-constituents, in aqueous and chloroform extracts, of Withania coagulans Dunal in experimental type 2 diabetes mellitus in rats. Hum Exp Toxicol 2010; 29:653-8. [DOI: 10.1177/0960327109359638] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Withania coagulans is used in indigenous system of medicine in several conditions, and its aqueous extract alone has reported antihyperglycemic activity. As per the principles of Indigenous System of Medicine, the combined use of aqueous and chloroform extracts of W coagulans fruits, containing multi-constituents, has been evaluated for the effect on blood glucose, lipid profile and body weight in type 2 diabetic rats. The aqueous and chloroform extracts were prepared by simple maceration and hot refluxing using Soxhlet apparatus, respectively. They were administered orally singly and concurrently as combination, once daily, a dose of 1 g kg —1 for 14 days in different groups of normoglycemic and hyperglycemic rats. Orally normal saline 1 mL 100g— 1, and Metformin 500 mg kg—1, were used as control and standard, respectively. Aqueous extract showed highly significant (p < .01) decrease in the blood glucose (52%), triglyceride, total cholesterol, LDL and VLDL level and highly significant (p < .01) increase in HDL level. The antihyperglycemic effect was found slightly (6%) superior to metformin. The combination of aqueous and chloroform extracts showed highly significant (p < .01) decrease in the blood glucose (55%), triglyceride, total cholesterol, LDL and VLDL levels, and a highly significant (p < .01) increase in HDL level. The antihyperglycemic effect being better than Metformin and aqueous extracts, 9% and 3%, respectively.
Collapse
Affiliation(s)
- Quaisul Hoda
- Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
| | | | - Mohammad Akhtar
- Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
| | - Abul Kalam Najmi
- Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
| | - KK Pillai
- Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India
| | - Shibli Jameel Ahmad
- Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India,
| |
Collapse
|
3
|
Hao J, Shen W, Tian C, Liu Z, Ren J, Luo C, Long J, Sharman E, Liu J. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Cell Mol Med 2008; 13:701-11. [PMID: 18410524 PMCID: PMC3822877 DOI: 10.1111/j.1582-4934.2008.00342.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The development of type 2 diabetes is accompanied by decreased immune function and the mechanisms are unclear. We hypothesize that oxidative damage and mitochondrial dysfunction may play an important role in the immune dysfunction in diabetes. In the present study, we investigated this hypothesis in diabetic Goto-Kakizaki rats by treatment with a combination of four mitochondrial-targeting nutrients, namely, R-α-lipoic acid, acetyl-L-carnitine, nicotinamide and biotin. We first studied the effects of the combination of these four nutrients on immune function by examining cell proliferation in immune organs (spleen and thymus) and immunomodulating factors in the plasma. We then examined, in the plasma and thymus, oxidative damage biomarkers, including lipid peroxidation, protein oxidation, reactive oxygen species, calcium and antioxidant defence systems, mitochondrial potential and apoptosis-inducing factors (caspase 3, p53 and p21). We found that immune dysfunction in these animals is associated with increased oxidative damage and mitochondrial dysfunction and that the nutrient treatment effectively elevated immune function, decreased oxidative damage, enhanced mitochondrial function and inhibited the elevation of apoptosis factors. These effects are comparable to, or greater than, those of the anti-diabetic drug pioglitazone. These data suggest that a rational combination of mitochondrial-targeting nutrients may be effective in improving immune function in type 2 diabetes through enhancement of mitochondrial function, decreased oxidative damage, and delayed cell death in the immune organs and blood.
Collapse
Affiliation(s)
- Jiejie Hao
- Institute for Nutritional Science, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, China
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Babel N, Cherepnev G, Kowalenko A, Horstrup J, Volk HD, Reinke P. Nonimmunologic complications and gene polymorphisms of immunoregulatory cytokines in long-term renal transplants. Kidney Int 2005; 66:428-32. [PMID: 15200452 DOI: 10.1111/j.1523-1755.2004.00749.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND While the influence of cytokine gene polymorphisms on immunologic complications after organ transplantation is widely evaluated, little is known about predictive value of cytokine genotype for the development of nonimmunologic post-transplant complications: hypertension, dyslipoproteinemia, diabetes mellitus, hyperuricemia. METHODS The -1082IL-10, -308TNF-alpha, transforming growth factor-beta1 (TGF-beta1) (codon 10, 25), -174IL-6, +874IFN-gamma gene single nucleotide polymorphisms (SNP) were studied in 278 long-term renal transplants by polymerase chain reaction-sequence specific primer (PCR-SSP) with respect to nonimmunologic post-transplant complications. RESULTS Significant association of the TGF-beta (codon 25) GG genotype with hyperuricemia (P= 0.0013) and dyslipoproteinemia (P= 0.0171) was found. The TGF-beta1 (codon 25) CG genotype was detected more frequently in patients with normal uric acid levels. The +874IFN-gamma AA genotype was associated with type 2/steroid-induced diabetes (P= 0.0127). Frequency of the -1082IL-10 AG genotype was significantly higher in hyperuricemic patients versus controls (P= 0.0022). No associations of polymorphisms in the tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), TGF-beta codon 10 genes with hyperuricemia, dyslipoproteinemia, or diabetes were detected. We failed to observe significant differences in cytokine genotype distribution between hypertensive and normotensive patients. CONCLUSION We established an association of particular cytokine genotypes with nonimmunologic post-transplant complications. This supports an idea that assessment of cytokine SNPs may allow more accurate prediction of nonimmunologic complications and appropriate adjustment of pre-emptive treatments in long-term transplant patients.
Collapse
Affiliation(s)
- Nina Babel
- Department of Nephrology and Internal Intensive Care, Clinic of Internal Medicine, Charité-Campus Virchow, Humboldt University of Berlin, Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
5
|
OHNO H, ISHIHARA Y, ARAI T, YAMAMURA H, TOTANI N, UEDA T. Effects of <i>Bifidobacterium bifidum</i> G9-1 on Hypercholesterolemic and Obese Diabetic Animal Models. Biosci Microflora 2004. [DOI: 10.12938/bifidus.23.109] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- Hiroshi OHNO
- Research & Development Department, Biofermin Pharmaceutical Co., Ltd
| | - Yoko ISHIHARA
- Research & Development Department, Biofermin Pharmaceutical Co., Ltd
| | - Teruhiko ARAI
- Research & Development Department, Biofermin Pharmaceutical Co., Ltd
| | - Hideki YAMAMURA
- Research & Development Department, Biofermin Pharmaceutical Co., Ltd
| | - Nagao TOTANI
- Department of Nutritional Physiology, Faculty of Nutrition, Kobe Gakuin University
| | - Takashi UEDA
- Department of Nutritional Physiology, Faculty of Nutrition, Kobe Gakuin University
| |
Collapse
|
6
|
Maltezos E, Papazoglou D, Exiara T, Papazoglou L, Karathanasis E, Christakidis D, Ktenidou-Kartali S. Tumour necrosis factor-alpha levels in non-diabetic offspring of patients with type 2 diabetes mellitus. J Int Med Res 2002; 30:576-83. [PMID: 12526284 DOI: 10.1177/147323000203000605] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Tumour necrosis factor-alpha (TNF-alpha) is considered to be involved in the insulin resistance of type 2 diabetes mellitus. The offspring of patients with type 2 diabetes mellitus are at increased risk of developing diabetes and several metabolic abnormalities, but the underlying defects responsible are not known. We studied serum TNF-alpha levels in 30 healthy non-diabetic offspring of type 2 diabetic parents (group A), and the relationship between TNF-alpha levels and variables associated with insulin resistance and diabetes. For comparison, 30 healthy offspring of non-diabetic parents (group B) were also studied. The median serum concentration of TNF-alpha was significantly higher in group A than in group B, 3.5 pg/ml compared with 2.0 pg/ml, respectively. The individuals of group A also had significantly elevated levels of glycosylated haemoglobin, fasting glucose, glucose 2 h after an oral glucose tolerance test and triglycerides. We conclude that serum TNF-alpha concentration is significantly elevated in non-diabetic offspring of type 2 diabetics and this may predict later impairment of insulin action in these individuals.
Collapse
Affiliation(s)
- E Maltezos
- Second Department of Internal Medicine, Democritus University of Thrace, Regional Hospital of Alexandroupolis, Alexandroupolis, Greece.
| | | | | | | | | | | | | |
Collapse
|
7
|
Oguri S, Motegi K, Iwakura Y, Endo Y. Primary role of interleukin-1 alpha and interleukin-1 beta in lipopolysaccharide-induced hypoglycemia in mice. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 2002; 9:1307-12. [PMID: 12414765 PMCID: PMC130127 DOI: 10.1128/cdli.9.6.1307-1312.2002] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Within a few hours of its injection into mice, lipopolysaccharide (LPS) induces hypoglycemia and the production of various cytokines. We previously found that interleukin-1 alpha (IL-1 alpha), IL-1 beta, and tumor necrosis factor alpha (TNF-alpha) induce hypoglycemia and that the minimum effective dose of IL-1 alpha or IL-1 beta is about 1/1000 that of TNF-alpha. In the present study, we examined the contribution made by IL-1 to the hypoglycemic action of LPS. Nine other cytokines tested were all inactive at inducing hypoglycemia. LPS produced hypoglycemia in mice deficient in either IL-1 alpha or IL-1 beta but not in mice deficient in both cytokines (IL-1 alpha and -1 beta knockout [IL-1 alpha/beta KO] mice). IL-1 alpha, IL-1 beta, and TNF-alpha induced hypoglycemia in IL-1 alpha/beta KO mice, as they did in normal control mice. The LPS-induced elevation of serum cortisol was weaker in IL-1 alpha/beta KO mice than in control mice, and, in the latter, serum cortisol was markedly raised while blood glucose was declining. IL-1 alpha decreased blood glucose both in NOD mice (which have impaired insulin production) and in KK-Ay mice (insulin resistant). These results suggest that (i). cortisol may not be involved in mediating the resistance of IL-1 alpha/beta KO mice to the hypoglycemic action of LPS, (ii). as a mediator, IL-1 is a prerequisite for the hypoglycemic action of LPS, (iii). IL-1 alpha and IL-1 beta perform mutual compensation, and (iv). IL-1 plays a role as the primary stimulator of the many anabolic reactions required for the elaboration of immune responses against infection.
Collapse
Affiliation(s)
- Senri Oguri
- Departments of Pharmacology. Maxillofacial and Plastic Surgery, Graduate School of Dentistry, Tohoku University, 4-1 Seiryo-Machi, Aoba-Ku, Sendai 980-8575, Japan
| | | | | | | |
Collapse
|
8
|
Muto G, Satoh J, Muto Y, Takahashi K, Nakazawa T, Sagara M, Miyaguchi S, Fukuzawa M, Qiang X, Sakata Y, Takizawa Y, Li Y, Bando S, Housai T, Tamagawa A, Toyota T. Adjuvant-induced improvement of glucose intolerance in type 2 diabetic KK-Ay mice through interleukin-1 and tumor necrosis factor-alpha. Clin Immunol 2000; 97:259-65. [PMID: 11112365 DOI: 10.1006/clim.2000.4928] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We reported that administration of complete Freund's adjuvant (CFA) improved glucose tolerance test (GTT) results in obese diabetic KK-Ay mice. In this study, we investigated its mechanism. An injection with CFA remarkably improved GTT for more than a week in KK-Ay mice, although insulin response was not changed compared with saline controls. The hypoglycemic effect of insulin was significantly, but partially, potentiated in the CFA-treated mice compared with the controls, suggesting that CFA stimulated insulin-mediated and non-insulin-mediated glucose disposal. Improvement in the GTT with CFA was partially transferable to nontreated mice by peritoneal exudative cells, but not spleen or lymph node cells. Pretreatment with anti-interleukin (IL)-1 alpha and -1 beta antibodies or anti-tumor necrosis factor (TNF)-alpha antibody significantly abrogated the improvement in the GTT with CFA. The results indicate that CFA-induced improvement in glucose intolerance in KK-Ay mice was mediated at least by IL-1 and TNF-alpha.
Collapse
Affiliation(s)
- G Muto
- The Third Department of Internal Medicine, Tohoku University School of Medicine, 1-1 Seiryo-machi, Sendai, Miyagi, 980-8574, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|